Status:
ACTIVE_NOT_RECRUITING
The PROMISE Survey
Lead Sponsor:
University Hospital, Basel, Switzerland
Conditions:
Prolactinoma
Pituitary Tumor
Eligibility:
All Genders
18+ years
Brief Summary
The PROMISE Survey was developed to systematically assess the real-world experiences, treatment preferences, side effects, and outcomes from both patients and physicians dealing with prolactinomas. Th...
Detailed Description
Background Prolactinomas are the most common hormone-producing pituitary tumors, causing symptoms like menstrual irregularities, infertility, galactorrhea, and reduced libido due to elevated prolacti...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Prolactinoma patients
- Prolactinoma treating physicians including endocrinologists and neurosurgeons
Exclusion
Key Trial Info
Start Date :
June 13 2025
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 30 2026
Estimated Enrollment :
530 Patients enrolled
Trial Details
Trial ID
NCT06936813
Start Date
June 13 2025
End Date
March 30 2026
Last Update
January 8 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Basel
Basel, Switzerland, 4031